As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.

LOAd703, an engineered version of adenovirus serotype 5/35, is double-armed with two transgenes—TMZ-CD40L ... cells to attack cancers cells. Systemically, they lead to migration of dendritic ...

Treated recipients received either 3 mg/kg rapamycin intraperitoneally for the first 14 d after transplantation (days 0-13) and/or 0.25 mg/dose CD40L-specific ... male spleen cells into female ...